These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 15230947)

  • 1. Effectiveness of factor VIII infusions in haemophilia A patients with high responding inhibitors.
    Kasuda S; Tanaka I; Shima M; Matsumoto T; Sakurai Y; Nishiya K; Giles AR; Yoshioka A
    Haemophilia; 2004 Jul; 10(4):341-6. PubMed ID: 15230947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The utility of activated partial thromboplastin time (aPTT) clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity (FVIII:C).
    Shima M; Matsumoto T; Fukuda K; Kubota Y; Tanaka I; Nishiya K; Giles AR; Yoshioka A
    Thromb Haemost; 2002 Mar; 87(3):436-41. PubMed ID: 11916076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A.
    Kempton CL; Abshire TC; Deveras RA; Hoots WK; Gill JC; Kessler CM; Key NS; Konkle BA; Kuriakose P; Macfarlane DE; Bergman G
    Haemophilia; 2012 Sep; 18(5):798-804. PubMed ID: 22512291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor VIII: C (FVIII: C) recovery and half-life after infusion of steam-treated high purity factor VIII concentrate in severe hemophilia A--comparison of one-stage assay, two-stage assay and a chromogenic substrate assay.
    Hellstern P; Kiehl R; Miyashita C; Schwerdt H; von Blohn G; Köhler M; Büttner M; Wenzel E
    Thromb Haemost; 1986 Dec; 56(3):353-9. PubMed ID: 3105109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clot waveform analysis using CS-2000i™ distinguishes between very low and absent levels of factor VIII activity in patients with severe haemophilia A.
    Matsumoto T; Nogami K; Tabuchi Y; Yada K; Ogiwara K; Kurono H; Arai N; Shima M
    Haemophilia; 2017 Sep; 23(5):e427-e435. PubMed ID: 28750470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetics of factor VIII:C inhibitors and treatment response in severe hemophilia A patients.
    Luna-Záizar H; Esparza-Flores MA; López-Guido B; Aguilar-López LB; Cortés Alvarez CR; Jaloma-Cruz AR
    Int J Lab Hematol; 2009 Dec; 31(6):673-82. PubMed ID: 18771497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid decrease in high titer of factor VIII inhibitors upon immunosuppressive treatment in severe postpartum acquired hemophilia A.
    Pejsa V; Grgurević I; Kusec R; Gaćina P
    Croat Med J; 2004 Apr; 45(2):213-6. PubMed ID: 15103761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thawed cryoprecipitate stored for 6 h at room temperature: a potential alternative to factor VIII concentrate for continuous infusion.
    Pesquera-Lepatan LM; Hernandez FG; Lim RD; Chua MN
    Haemophilia; 2004 Nov; 10(6):684-8. PubMed ID: 15569162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
    Kubisz P; Plamenová I; Hollý P; Stasko J
    Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous infusion of factor concentrates in children with haemophilia A in comparison with bolus injections.
    Bidlingmaier C; Deml MM; Kurnik K
    Haemophilia; 2006 May; 12(3):212-7. PubMed ID: 16643203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central venous access devices for paediatric patients with haemophilia: a single-institution experience.
    Titapiwatanakun R; Moir C; Pruthi RK; Stavlo PL; Schmidt KA; Rodriguez V
    Haemophilia; 2009 Jan; 15(1):168-74. PubMed ID: 19149849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of factor VIII on overall coagulability and fibrinolytic potential of haemophilic plasma as measured by global assay: monitoring in haemophilia A.
    Goldenberg NA; Hathaway WE; Jacobson L; McFarland K; Manco-Johnson MJ
    Haemophilia; 2006 Nov; 12(6):605-14. PubMed ID: 17083510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94-9027) for haemophilia A.
    Gu JM; Ramsey P; Evans V; Tang L; Apeler H; Leong L; Murphy JE; Laux V; Myles T
    Haemophilia; 2014 Jul; 20(4):593-600. PubMed ID: 24471985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New quantitative aPTT waveform analysis and its application in laboratory management of haemophilia A patients.
    Milos M; Coen Herak D; Zupancic-Salek S; Zadro R
    Haemophilia; 2014 Nov; 20(6):898-904. PubMed ID: 25273337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin SDH in previously treated patients with severe haemophilia A.
    Wolf DM; Rokicka-Milewska R; Lopaciuk S; Skotnicki AB; Klukowska A; Laguna P; Windyga J; Kotitschke R; Struff WG
    Haemophilia; 2004 Sep; 10(5):438-48. PubMed ID: 15357768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Catastrophic microangiopathy induced by high-titre factor VIII inhibitors after liver transplantation for haemophilia A with cirrhosis.
    Khakhar AK; Chan NG; Allan DS; Chakrabarti S; McAlister VC
    Haemophilia; 2005 Nov; 11(6):623-8. PubMed ID: 16236113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay.
    Matsumoto T; Shima M; Takeyama M; Yoshida K; Tanaka I; Sakurai Y; Giles AR; Yoshioka A
    J Thromb Haemost; 2006 Feb; 4(2):377-84. PubMed ID: 16420569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infusion rates of recombinant FVIII-FS with PEGylated liposomes in haemophilia A.
    Martinowitz U; Lalezari S; Luboshitz J; Lubetsky A; Spira J
    Haemophilia; 2008 Sep; 14(5):1122-4. PubMed ID: 18564190
    [No Abstract]   [Full Text] [Related]  

  • 19. Measurement of global haemostasis in severe haemophilia A following factor VIII infusion.
    Lewis SJ; Stephens E; Florou G; Macartney NJ; Hathaway LS; Knipping J; Collins PW
    Br J Haematol; 2007 Sep; 138(6):775-82. PubMed ID: 17672884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Normalization of factor VIII levels in a patient with mild haemophilia A during a 35-year period.
    Mainwaring CJ; Evans J; Chana J; Lewis H
    Haemophilia; 2006 Nov; 12(6):668-71. PubMed ID: 17083519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.